Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
Formula attenuates 99% of 365 coronaviruses in computer models
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
High level of vaccine efficacy maintained over a 6-month period of surveillance
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Subscribe To Our Newsletter & Stay Updated
